Loading
Expert Witness Guides
12 min read
Areas of Expertise :
Toxicology, Epidemiology, Herbicides, Neurology, Product Liability
Published Date:
Last Modified Date:
The federal Paraquat litigation shows how exclusion of a key causation expert under Rule 702 can directly affect whether a toxic tort case proceeds to trial. This article examines why the court excluded the plaintiffs’ sole general causation expert in four trial-selection cases, how methodological issues involving study selection and scientific analysis shaped the ruling, and what the decision means for expert preparation, admissibility strategy, and summary judgment risk.
Expert testimony often determines whether a toxic tort lawsuit reaches a jury. In cases involving alleged exposure to hazardous substances, plaintiffs typically rely on qualified experts to explain whether a substance is capable of causing the claimed injury and whether the available scientific evidence supports that conclusion through reliable methods.
Those issues took center stage in the federal Paraquat multidistrict litigation (MDL). On April 17, 2024, Chief U.S. District Judge Nancy J. Rosenstengel excluded the testimony of Dr. Martin Wells, the plaintiffs' sole general causation expert in four trial-selection cases. Although the court found Dr. Wells qualified to testify within his field of expertise, it concluded that the plaintiffs had not established, by a preponderance of the evidence, that his general causation opinions satisfied the reliability requirements of Federal Rule of Evidence 702. In a separate order issued the same day, the court granted summary judgment and dismissed those four trial-selection cases with prejudice.
Although the rulings represented a significant setback for the affected plaintiffs, they did not resolve the entire Paraquat MDL or establish that paraquat can never cause Parkinson's disease. Instead, the decisions illustrate how federal courts evaluate expert methodology, reasoning, and scientific support before permitting expert testimony to reach a jury.
For attorneys handling complex scientific litigation, the decisions reinforce an important practical point: expert admissibility should be considered throughout the life of a case because, when expert testimony is essential to proving causation, a Rule 702 ruling can determine whether the case proceeds to trial.
The federal Paraquat lawsuits were coordinated in the United States District Court for the Southern District of Illinois as In re: Paraquat Products Liability Litigation, MDL No. 3004.
The plaintiffs alleged that exposure to paraquat dichloride, a restricted-use herbicide, caused them to develop Parkinson's disease. According to the court's April 17, 2024 opinion, the MDL involved more than 5,000 individual plaintiffs at that time.
Under the federal multidistrict litigation process established by 28 U.S.C. § 1407, the transferred cases were coordinated before a single federal court for consolidated or coordinated pretrial proceedings while remaining separate member cases. The purpose of the MDL process is to promote efficient resolution of common factual issues without merging the individual lawsuits into a single action.
In April 2022, the court selected six member cases for case-specific discovery. Two of those cases, Walkington and Marx, were later voluntarily dismissed with prejudice. The remaining four completed fact and expert discovery and became the first trial-selection cases:
Those four cases ultimately became the focus of the court's Rule 702 analysis.
Neurotoxicology
Environmental Toxicology
Chemical Exposures
Exposure Assessments
Causation Analysis
Human Health Risk Assessment HHRA
Expert testimony often determines whether a toxic tort lawsuit reaches a jury. In cases involving alleged exposure to hazardous substances, plaintiffs typically rely on qualified experts to explain whether a substance is capable of causing the claimed injury and whether the available scientific evidence supports that conclusion through reliable methods.
Those issues took center stage in the federal Paraquat multidistrict litigation (MDL). On April 17, 2024, Chief U.S. District Judge Nancy J. Rosenstengel excluded the testimony of Dr. Martin Wells, the plaintiffs' sole general causation expert in four trial-selection cases. Although the court found Dr. Wells qualified to testify within his field of expertise, it concluded that the plaintiffs had not established, by a preponderance of the evidence, that his general causation opinions satisfied the reliability requirements of Federal Rule of Evidence 702. In a separate order issued the same day, the court granted summary judgment and dismissed those four trial-selection cases with prejudice.
Although the rulings represented a significant setback for the affected plaintiffs, they did not resolve the entire Paraquat MDL or establish that paraquat can never cause Parkinson's disease. Instead, the decisions illustrate how federal courts evaluate expert methodology, reasoning, and scientific support before permitting expert testimony to reach a jury.
For attorneys handling complex scientific litigation, the decisions reinforce an important practical point: expert admissibility should be considered throughout the life of a case because, when expert testimony is essential to proving causation, a Rule 702 ruling can determine whether the case proceeds to trial.
The federal Paraquat lawsuits were coordinated in the United States District Court for the Southern District of Illinois as In re: Paraquat Products Liability Litigation, MDL No. 3004.
The plaintiffs alleged that exposure to paraquat dichloride, a restricted-use herbicide, caused them to develop Parkinson's disease. According to the court's April 17, 2024 opinion, the MDL involved more than 5,000 individual plaintiffs at that time.
Under the federal multidistrict litigation process established by 28 U.S.C. § 1407, the transferred cases were coordinated before a single federal court for consolidated or coordinated pretrial proceedings while remaining separate member cases. The purpose of the MDL process is to promote efficient resolution of common factual issues without merging the individual lawsuits into a single action.
In April 2022, the court selected six member cases for case-specific discovery. Two of those cases, Walkington and Marx, were later voluntarily dismissed with prejudice. The remaining four completed fact and expert discovery and became the first trial-selection cases:
Those four cases ultimately became the focus of the court's Rule 702 analysis.
The defendants moved to exclude Dr. Martin Wells under Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc..
Dr. Wells served as the plaintiffs' only general causation expert in the four trial-selection cases. He concluded that occupational exposure to paraquat can cause Parkinson's disease. His opinion relied primarily on a meta-analysis of seven case-control epidemiological studies, followed by a broader weight-of-the-evidence evaluation using the Bradford Hill considerations to assess whether the available scientific evidence supported a causal relationship.
Before issuing its ruling, the court conducted an extensive review of the record. That review included written briefing, expert reports, deposition testimony, documentary evidence, and a four-day evidentiary hearing during which Dr. Wells testified.
Although the court found Dr. Wells qualified as an expert in his field, it concluded that the plaintiffs had not demonstrated that his general causation opinions satisfied Rule 702's reliability requirements. The opinion identified several methodological concerns, including:
Importantly, the court did not reject meta-analysis as a scientific method or the Bradford Hill framework itself. Instead, it concluded that Dr. Wells had not applied those accepted methodologies reliably to the scientific record presented in the four trial-selection cases.
The decision illustrates a fundamental principle of Rule 702. Federal courts generally do not determine whether an expert has reached the scientifically correct conclusion. Rather, they evaluate whether the proffered opinions are supported by sufficient facts or data, whether the expert employed reliable principles and methods, and whether those methods were applied reliably to the facts of the case.
The court's analysis also demonstrates that methodological transparency is critical in scientifically complex litigation. Where an expert relies on multiple studies, courts may closely examine why certain research was included, why other evidence was discounted, how conflicting findings were addressed, and whether the expert consistently applied the stated methodology throughout the analysis.
These issues were central to the court's evaluation of Dr. Wells's opinions. The court concluded that the plaintiffs had not met their burden of establishing admissibility under Rule 702 by a preponderance of the evidence, resulting in exclusion of his general causation testimony.
Federal Rule of Evidence 702 governs the admissibility of expert testimony in federal court. Under the current rule, the party offering expert testimony must establish, by a preponderance of the evidence, that the rule's admissibility requirements have been satisfied.
To be admissible, expert testimony must:
The 2023 amendment to Rule 702 clarified that the proponent of expert testimony bears the burden of establishing these admissibility requirements by a preponderance of the evidence. The Advisory Committee emphasized that the amendment was intended to clarify the proper application of Rule 702 rather than create a new substantive standard.
The Paraquat rulings demonstrate why methodology deserves as much attention as an expert's qualifications. Courts may closely examine how an expert selected supporting studies, addressed conflicting scientific evidence, explained methodological choices, and connected the scientific record to the ultimate opinions offered. Even highly qualified experts may have testimony excluded if the court determines that the methodology or its application does not satisfy Rule 702.
One of the central issues in the Paraquat litigation was general causation, a concept that frequently arises in toxic tort, pharmaceutical, product liability, and other scientifically complex cases.
General causation asks whether a substance can cause the type of injury alleged.
Specific causation asks whether the plaintiff's exposure to the substance was a cause of that individual's alleged injury under the applicable substantive law.
Although the precise proof requirements depend on the governing law and the facts of each case, many toxic tort claims require admissible expert testimony on general causation before a plaintiff can establish that a particular exposure caused an individual's illness.
To develop opinions on general causation, experts may evaluate several categories of scientific evidence, including:
The Paraquat decisions illustrate that identifying studies reporting an association is only one part of the analysis. When evaluating an extensive scientific record, experts should explain why particular studies were included or excluded, discuss important methodological limitations, address significant contrary evidence, and demonstrate how the overall methodology supports the conclusions offered.
The court's opinion illustrates that transparency in scientific reasoning can be just as important as the scientific literature itself. A court evaluating expert testimony under Rule 702 may examine not only the studies an expert relied upon but also whether the expert consistently applied the stated methodology throughout the analysis.
After excluding Dr. Wells's testimony, the court separately considered the defendants' motion for summary judgment.
The plaintiffs acknowledged that Dr. Wells was their only general causation expert in the four trial-selection cases. Without admissible expert testimony establishing general causation, they could not prove an essential element of their claims under the applicable substantive law. The court therefore granted summary judgment and dismissed all four trial-selection cases with prejudice.
The sequence of the court's rulings is important. The exclusion order did not itself dispose of the four trial-selection cases or terminate the broader Paraquat MDL. Instead, the court issued a separate summary judgment order after concluding that, without admissible expert testimony on general causation, the plaintiffs could not establish an essential element of their claims.
For attorneys, the rulings illustrate the close relationship between Rule 702 motions and dispositive motions. When expert testimony supplies the only admissible evidence supporting an essential element of a claim, the outcome of a Rule 702 motion may significantly affect whether the case proceeds to trial.
The decisions also highlight the importance of evaluating evidentiary issues throughout litigation. Waiting until expert reports have been exchanged or a Rule 702 motion has been filed may leave little opportunity to address methodological concerns that could prove outcome-determinative.
The April 17, 2024 orders resolved only the four trial-selection cases. They did not dismiss every lawsuit pending in MDL No. 3004.
In its summary judgment order, the court directed the parties to identify additional member cases for continued discovery and case management. Accordingly, the rulings should not be described as ending the federal Paraquat litigation.
The court also did not make a universal scientific finding that paraquat cannot cause Parkinson's disease. Rather, it concluded only that the expert testimony presented in the four trial-selection cases did not satisfy Rule 702's admissibility requirements.
That distinction is important. Any future Rule 702 determination would depend on the qualifications of the expert, the opinions offered, the supporting scientific record, and whether the expert reliably applied accepted methodology to the facts presented. Any future expert testimony would still have to satisfy applicable evidentiary standards, disclosure requirements, scheduling orders, and other procedural requirements.
Likewise, the April 2024 rulings interpreted and applied Federal Rule of Evidence 702 in federal court. Standing alone, they do not determine whether expert testimony would be admitted in a separate state court proceeding governed by different evidentiary rules or judicial precedent.
For litigators, the decisions serve as a reminder that expert admissibility rulings are highly fact-specific. Courts evaluate the record presented in the particular case before them, and the admissibility of expert testimony depends on whether the proponent satisfies the applicable evidentiary standards.
The Paraquat decisions provide several practical lessons for attorneys handling cases that depend on complex scientific expert testimony.
Early review of an expert's methodology can help identify potential Rule 702 vulnerabilities before expert reports are finalized. Addressing methodological questions early allows counsel to evaluate and address potential admissibility issues while preserving the expert's independent professional judgment.
Courts may closely examine why an expert relied on certain studies while assigning less weight to others. A well-supported explanation for those decisions, including how conflicting evidence was evaluated, can strengthen the credibility and reliability of the overall analysis.
The Paraquat decisions demonstrate that courts examine far more than an expert's credentials. Reliable opinions depend not only on the methods used but also on whether those methods were consistently and transparently applied to the available scientific evidence.
When expert testimony provides the only admissible evidence supporting an essential element of a claim, Rule 702 issues may affect far more than evidentiary rulings. Early evaluation of those issues can help attorneys make informed decisions regarding expert preparation, discovery strategy, motion practice, and overall case management.
Viewed as a whole, the Paraquat rulings underscore the importance of careful expert preparation, transparent scientific reasoning, and rigorous application of accepted methodologies in complex litigation involving scientific evidence.
Although the Paraquat rulings arose from a toxic tort multidistrict litigation, the court's Rule 702 analysis offers guidance for many cases involving complex scientific, technical, medical, or financial evidence.
The decisions reinforce that successful expert testimony depends on more than impressive credentials. Courts also evaluate whether the expert:
Attorneys presenting expert testimony should be prepared to demonstrate:
Likewise, attorneys challenging expert testimony frequently focus on these same issues. Questions involving study selection, analytical gaps, unsupported assumptions, inconsistent methodology, or inadequate explanation often become central to Rule 702 motions.
The Paraquat rulings do not establish a new legal standard governing expert testimony. Instead, they illustrate how long-established Rule 702 and Daubert principles, as clarified by the 2023 amendment to Rule 702, may significantly influence litigation when expert testimony is essential to proving causation.
The April 2024 Paraquat decisions demonstrate how Federal Rule of Evidence 702 can shape the outcome of complex toxic tort litigation. By excluding the plaintiffs' only general causation expert in the four trial-selection cases, the court concluded that the plaintiffs no longer had admissible expert evidence supporting an essential element of their claims. The court subsequently granted summary judgment and dismissed those four cases with prejudice.
Equally important, the rulings illustrate what they do not decide. The court did not dismiss the entire Paraquat multidistrict litigation, reject meta-analysis or the Bradford Hill framework as generally accepted methodologies, or determine that paraquat can never cause Parkinson's disease. Instead, the decisions focused on whether the expert opinions offered in those four cases were supported by sufficient facts or data, reliable principles and methods, and a reliable application of those methods under Rule 702.
For attorneys handling scientifically complex litigation, the broader lesson is clear. Strong credentials alone are not enough to satisfy Rule 702. Courts may closely examine every significant methodological step supporting an expert's opinions, including study selection, evaluation of conflicting evidence, analytical reasoning, and the application of accepted scientific methods. Careful expert selection, thoughtful report preparation, and early evaluation of potential Rule 702 issues remain essential components of effective litigation strategy.
Why did the judge exclude Dr. Wells's testimony?
The court concluded that the plaintiffs did not establish, by a preponderance of the evidence, that Dr. Wells's general causation opinions satisfied Rule 702. Although the court found him qualified in his field, it identified reliability concerns regarding his study selection, meta-analysis, weight-of-the-evidence evaluation, and application of the Bradford Hill considerations.
Did the court rule that paraquat does not cause Parkinson's disease?
No. The court ruled only that the expert testimony presented in the four trial-selection cases did not satisfy Rule 702's admissibility requirements. It did not decide, as a universal scientific or legal proposition, that paraquat is incapable of causing Parkinson's disease.
Why did expert exclusion result in summary judgment?
Dr. Wells was the plaintiffs' only general causation expert in the four trial-selection cases. After his testimony was excluded, the plaintiffs no longer had admissible expert evidence supporting an essential element of their claims. The court therefore entered a separate summary judgment order dismissing those four cases with prejudice.
Does this decision resolve every Paraquat lawsuit?
No. The April 17, 2024 orders resolved only the four trial-selection cases. The court directed the parties to identify additional member cases for continued discovery and case management within the multidistrict litigation.
The defendants moved to exclude Dr. Martin Wells under Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc..
Dr. Wells served as the plaintiffs' only general causation expert in the four trial-selection cases. He concluded that occupational exposure to paraquat can cause Parkinson's disease. His opinion relied primarily on a meta-analysis of seven case-control epidemiological studies, followed by a broader weight-of-the-evidence evaluation using the Bradford Hill considerations to assess whether the available scientific evidence supported a causal relationship.
Before issuing its ruling, the court conducted an extensive review of the record. That review included written briefing, expert reports, deposition testimony, documentary evidence, and a four-day evidentiary hearing during which Dr. Wells testified.
Although the court found Dr. Wells qualified as an expert in his field, it concluded that the plaintiffs had not demonstrated that his general causation opinions satisfied Rule 702's reliability requirements. The opinion identified several methodological concerns, including:
Importantly, the court did not reject meta-analysis as a scientific method or the Bradford Hill framework itself. Instead, it concluded that Dr. Wells had not applied those accepted methodologies reliably to the scientific record presented in the four trial-selection cases.
The decision illustrates a fundamental principle of Rule 702. Federal courts generally do not determine whether an expert has reached the scientifically correct conclusion. Rather, they evaluate whether the proffered opinions are supported by sufficient facts or data, whether the expert employed reliable principles and methods, and whether those methods were applied reliably to the facts of the case.
The court's analysis also demonstrates that methodological transparency is critical in scientifically complex litigation. Where an expert relies on multiple studies, courts may closely examine why certain research was included, why other evidence was discounted, how conflicting findings were addressed, and whether the expert consistently applied the stated methodology throughout the analysis.
These issues were central to the court's evaluation of Dr. Wells's opinions. The court concluded that the plaintiffs had not met their burden of establishing admissibility under Rule 702 by a preponderance of the evidence, resulting in exclusion of his general causation testimony.
Federal Rule of Evidence 702 governs the admissibility of expert testimony in federal court. Under the current rule, the party offering expert testimony must establish, by a preponderance of the evidence, that the rule's admissibility requirements have been satisfied.
To be admissible, expert testimony must:
The 2023 amendment to Rule 702 clarified that the proponent of expert testimony bears the burden of establishing these admissibility requirements by a preponderance of the evidence. The Advisory Committee emphasized that the amendment was intended to clarify the proper application of Rule 702 rather than create a new substantive standard.
The Paraquat rulings demonstrate why methodology deserves as much attention as an expert's qualifications. Courts may closely examine how an expert selected supporting studies, addressed conflicting scientific evidence, explained methodological choices, and connected the scientific record to the ultimate opinions offered. Even highly qualified experts may have testimony excluded if the court determines that the methodology or its application does not satisfy Rule 702.
One of the central issues in the Paraquat litigation was general causation, a concept that frequently arises in toxic tort, pharmaceutical, product liability, and other scientifically complex cases.
General causation asks whether a substance can cause the type of injury alleged.
Specific causation asks whether the plaintiff's exposure to the substance was a cause of that individual's alleged injury under the applicable substantive law.
Although the precise proof requirements depend on the governing law and the facts of each case, many toxic tort claims require admissible expert testimony on general causation before a plaintiff can establish that a particular exposure caused an individual's illness.
To develop opinions on general causation, experts may evaluate several categories of scientific evidence, including:
The Paraquat decisions illustrate that identifying studies reporting an association is only one part of the analysis. When evaluating an extensive scientific record, experts should explain why particular studies were included or excluded, discuss important methodological limitations, address significant contrary evidence, and demonstrate how the overall methodology supports the conclusions offered.
The court's opinion illustrates that transparency in scientific reasoning can be just as important as the scientific literature itself. A court evaluating expert testimony under Rule 702 may examine not only the studies an expert relied upon but also whether the expert consistently applied the stated methodology throughout the analysis.
After excluding Dr. Wells's testimony, the court separately considered the defendants' motion for summary judgment.
The plaintiffs acknowledged that Dr. Wells was their only general causation expert in the four trial-selection cases. Without admissible expert testimony establishing general causation, they could not prove an essential element of their claims under the applicable substantive law. The court therefore granted summary judgment and dismissed all four trial-selection cases with prejudice.
The sequence of the court's rulings is important. The exclusion order did not itself dispose of the four trial-selection cases or terminate the broader Paraquat MDL. Instead, the court issued a separate summary judgment order after concluding that, without admissible expert testimony on general causation, the plaintiffs could not establish an essential element of their claims.
For attorneys, the rulings illustrate the close relationship between Rule 702 motions and dispositive motions. When expert testimony supplies the only admissible evidence supporting an essential element of a claim, the outcome of a Rule 702 motion may significantly affect whether the case proceeds to trial.
The decisions also highlight the importance of evaluating evidentiary issues throughout litigation. Waiting until expert reports have been exchanged or a Rule 702 motion has been filed may leave little opportunity to address methodological concerns that could prove outcome-determinative.
The April 17, 2024 orders resolved only the four trial-selection cases. They did not dismiss every lawsuit pending in MDL No. 3004.
In its summary judgment order, the court directed the parties to identify additional member cases for continued discovery and case management. Accordingly, the rulings should not be described as ending the federal Paraquat litigation.
The court also did not make a universal scientific finding that paraquat cannot cause Parkinson's disease. Rather, it concluded only that the expert testimony presented in the four trial-selection cases did not satisfy Rule 702's admissibility requirements.
That distinction is important. Any future Rule 702 determination would depend on the qualifications of the expert, the opinions offered, the supporting scientific record, and whether the expert reliably applied accepted methodology to the facts presented. Any future expert testimony would still have to satisfy applicable evidentiary standards, disclosure requirements, scheduling orders, and other procedural requirements.
Likewise, the April 2024 rulings interpreted and applied Federal Rule of Evidence 702 in federal court. Standing alone, they do not determine whether expert testimony would be admitted in a separate state court proceeding governed by different evidentiary rules or judicial precedent.
For litigators, the decisions serve as a reminder that expert admissibility rulings are highly fact-specific. Courts evaluate the record presented in the particular case before them, and the admissibility of expert testimony depends on whether the proponent satisfies the applicable evidentiary standards.
The Paraquat decisions provide several practical lessons for attorneys handling cases that depend on complex scientific expert testimony.
Early review of an expert's methodology can help identify potential Rule 702 vulnerabilities before expert reports are finalized. Addressing methodological questions early allows counsel to evaluate and address potential admissibility issues while preserving the expert's independent professional judgment.
Courts may closely examine why an expert relied on certain studies while assigning less weight to others. A well-supported explanation for those decisions, including how conflicting evidence was evaluated, can strengthen the credibility and reliability of the overall analysis.
The Paraquat decisions demonstrate that courts examine far more than an expert's credentials. Reliable opinions depend not only on the methods used but also on whether those methods were consistently and transparently applied to the available scientific evidence.
When expert testimony provides the only admissible evidence supporting an essential element of a claim, Rule 702 issues may affect far more than evidentiary rulings. Early evaluation of those issues can help attorneys make informed decisions regarding expert preparation, discovery strategy, motion practice, and overall case management.
Viewed as a whole, the Paraquat rulings underscore the importance of careful expert preparation, transparent scientific reasoning, and rigorous application of accepted methodologies in complex litigation involving scientific evidence.
Although the Paraquat rulings arose from a toxic tort multidistrict litigation, the court's Rule 702 analysis offers guidance for many cases involving complex scientific, technical, medical, or financial evidence.
The decisions reinforce that successful expert testimony depends on more than impressive credentials. Courts also evaluate whether the expert:
Attorneys presenting expert testimony should be prepared to demonstrate:
Likewise, attorneys challenging expert testimony frequently focus on these same issues. Questions involving study selection, analytical gaps, unsupported assumptions, inconsistent methodology, or inadequate explanation often become central to Rule 702 motions.
The Paraquat rulings do not establish a new legal standard governing expert testimony. Instead, they illustrate how long-established Rule 702 and Daubert principles, as clarified by the 2023 amendment to Rule 702, may significantly influence litigation when expert testimony is essential to proving causation.
The April 2024 Paraquat decisions demonstrate how Federal Rule of Evidence 702 can shape the outcome of complex toxic tort litigation. By excluding the plaintiffs' only general causation expert in the four trial-selection cases, the court concluded that the plaintiffs no longer had admissible expert evidence supporting an essential element of their claims. The court subsequently granted summary judgment and dismissed those four cases with prejudice.
Equally important, the rulings illustrate what they do not decide. The court did not dismiss the entire Paraquat multidistrict litigation, reject meta-analysis or the Bradford Hill framework as generally accepted methodologies, or determine that paraquat can never cause Parkinson's disease. Instead, the decisions focused on whether the expert opinions offered in those four cases were supported by sufficient facts or data, reliable principles and methods, and a reliable application of those methods under Rule 702.
For attorneys handling scientifically complex litigation, the broader lesson is clear. Strong credentials alone are not enough to satisfy Rule 702. Courts may closely examine every significant methodological step supporting an expert's opinions, including study selection, evaluation of conflicting evidence, analytical reasoning, and the application of accepted scientific methods. Careful expert selection, thoughtful report preparation, and early evaluation of potential Rule 702 issues remain essential components of effective litigation strategy.
Why did the judge exclude Dr. Wells's testimony?
The court concluded that the plaintiffs did not establish, by a preponderance of the evidence, that Dr. Wells's general causation opinions satisfied Rule 702. Although the court found him qualified in his field, it identified reliability concerns regarding his study selection, meta-analysis, weight-of-the-evidence evaluation, and application of the Bradford Hill considerations.
Did the court rule that paraquat does not cause Parkinson's disease?
No. The court ruled only that the expert testimony presented in the four trial-selection cases did not satisfy Rule 702's admissibility requirements. It did not decide, as a universal scientific or legal proposition, that paraquat is incapable of causing Parkinson's disease.
Why did expert exclusion result in summary judgment?
Dr. Wells was the plaintiffs' only general causation expert in the four trial-selection cases. After his testimony was excluded, the plaintiffs no longer had admissible expert evidence supporting an essential element of their claims. The court therefore entered a separate summary judgment order dismissing those four cases with prejudice.
Does this decision resolve every Paraquat lawsuit?
No. The April 17, 2024 orders resolved only the four trial-selection cases. The court directed the parties to identify additional member cases for continued discovery and case management within the multidistrict litigation.
Neurotoxicology
Environmental Toxicology
Chemical Exposures
Exposure Assessments
Causation Analysis
Human Health Risk Assessment HHRA
Expert Witness Guides
Expert Witness Guides